Our participation in an Innovation Partnership in ATMPs of 81 million euros
Quality Assistance joins €81M Innovation Partnership to advance ATMPs.
We’re proud to be part of a groundbreaking €81 million Innovation Partnership focused on Advanced Therapy Medicinal Products (ATMPs). This ambitious initiative, led by BioWin and the Public Service of Wallonia, reflects a shared commitment to accelerating innovation in the field of advanced therapies.
Together, with 25 other partners, we’re contributing to 12 work packages spanning the entire ATMP value chain. The project aims to :
- Explore high-potential areas of scientific research,
- Strengthen preclinical and clinical development,
- Innovate in process design and quality control.
Our role in 2 strategic work packages
We’re proud to contribute to two key work packages with our scientific and analytical expertise:
- CARACT’EXO : in collaboration with Novadip, we’re leading the development of advanced analytical tools for exosome characterisation, a promising area in regenerative medicine.
- GUIDEPRO : in partnership with Eurogentec, we’re helping develop a robust methodology for producing guide RNAs used in CRISPR-based therapeutic gene editing.
Watch our R&D and Innovation Director, Arnaud Delobel, as he shares insights into our involvement in this transformative projects:
You must accept functional cookies to play the video. Change settings
